A5075653059- Acute Lymphoblastic Leukemia research
- Erythrocyte Function and Pathophysiology
- Schizophrenia research and treatment
- Bipolar Disorder and Treatment
- Rheumatoid Arthritis Research and Therapies
- Hemoglobinopathies and Related Disorders
- Pharmaceutical studies and practices
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Chronic Lymphocytic Leukemia Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Blood properties and coagulation
- Pharmacogenetics and Drug Metabolism
- Blood groups and transfusion
- Psoriasis: Treatment and Pathogenesis
- Computational Drug Discovery Methods
- Erythropoietin and Anemia Treatment
- Spondyloarthritis Studies and Treatments
- Hematopoietic Stem Cell Transplantation
- Chemotherapy-related skin toxicity
- Systemic Lupus Erythematosus Research
- Multiple Sclerosis Research Studies
- Statistical Methods in Clinical Trials
- Pulmonary Hypertension Research and Treatments
- Advanced Glycation End Products research
- Influenza Virus Research Studies
Boehringer Ingelheim (United States)
2019-2025
Metrum Research Group (United States)
2025
IP Australia
2015-2018
Uppsala University
2013-2015
University of Otago
2010-2013
Background: The drug candidate BI 730357 is a Biopharmaceutics Classification System (BCS) Class II compound showing atypical absorption after oral administration in fasted and fed healthy individuals, for which conventional traditional deconvolution methods could not explain formulation dependencies. Methods: A physiologically based pharmacokinetic (PBPK) model of was developed using the Open Systems Pharmacology (OSP) PBPK software tool PK-Sim®, describe pharmacokinetics subjects single...
ABSTRACT The shiny R package has enabled pharmacometrics (PMX) scientists to create and share interactive R‐based tools, or “shiny apps”. Initially, apps are developed ad hoc (i.e. project specific) provide simulations, their complexity have evolved be more general‐purpose “platform‐like” in recent years. Despite increased amount of features, an unexplored aspect is the design considerations for user interface experience (UI/UX) optimize end‐user interactivity enjoyment.
Mathematical models are routinely used in clinical pharmacology to study the pharmacokinetic and pharmacodynamic properties of a drug body. Identifiability these is an important requirement for success studies. classified into two types, structural identifiability related structure mathematical model deterministic which design. There existing approaches assessment fixed‐effects models, although their use appears uncommon literature. In this study, we develop informal unified approach...
Abstract BI 730357 is investigated as an oral treatment of plaque psoriasis. We analyzed the impact three dosage regimens on Psoriasis Area and Severity Index (PASI) response with modeling based phase I II data from 109 healthy subjects 274 patients moderate‐to‐severe The pharmacokinetics (PK) was characterized by a two‐compartment model dual absorption paths first‐order elimination. Higher baseline C‐reactive protein associated lower clearance generally had compared subjects. A bounded...
Schizophrenia is a common disease managed by range of interventions, with the primary treatment being antipsychotic medications (APS). Inadequate response, lack adherence, and/or adverse events often prevent optimal therapeutic effects or efficiency. Monitoring APS plasma concentrations can be used together full clinical evaluation to help improve patient care offer better options for patient. To enable interpretation individual risperidone and paliperidone concentrations, we developed...
Aim To assess the similarities in intracellular pharmacokinetics (PK) of methotrexate (MTX) red blood cells (RBCs) and other cell lines. Methods Three previously published PK models for MTX polyglutamate (MTXGlu2–5) concentrations were used: (i) a model kinetics RBCs, (ii) human breast cancer (HBCCs) (iii) various white (WBC) All three used to simulate response typical individual receiving 10 mg oral once weekly predicted steady-state (Css) time Css (tss) compared. Results The HBCC showed...
We describe a parametric time-to-event model for idiopathic pulmonary fibrosis (IPF) exacerbations and identify predictors of exacerbation risk using data obtained the tyrosine-kinase inhibitor nintedanib in two phase III studies (INPULSIS-1/2). Parametric survival analysis was performed on time to first (censoring day 372), with univariate select statistically significant covariates (P = 0.05). Multivariate covariate models were developed stepwise modeling forward inclusion 0.05) backward...
DZIF-10c (BI 767551) is a recombinant human monoclonal antibody of the IgG1 kappa isotype. It acts as SARS-CoV-2 neutralizing antibody. has been developed for both systemic exposure by intravenous infusion well specific to respiratory tract application an inhaled aerosol generated nebulizer. An integrated preclinical/clinical semi-mechanistic population pharmacokinetic model was characterize profile in circulation and lungs. To inform reduce uncertainty around lungs following different...